Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer

Cutaneous and Ocular Toxicology

Volumn 28, Issue 4, 2009, Pages 181-184

  Bustillo, Ivan ^a   Kaley, Kristin ^a   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Rash

Indexed keywords

ANTIHISTAMINIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CONSULTATION; DRUG ERUPTION; DRUG WITHDRAWAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FACE RASH; FEMALE; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; LOCAL SKIN REACTION; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EXANTHEMA; FACE; FEMALE; FILGRASTIM; HUMANS; NEUTROPENIA; PANCREATIC NEOPLASMS;

EID: 70449365741     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569520903178208     Document Type: Article

References (20)

1. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004;34:238-244
2. Burris HA 3rd, Moore MJ, Andersen J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413
3. www.drugs.com/sfx/gemcitabine-side-effects.html
4. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 2008;19:340-347
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966
6. Alvarez-Ruiz S, Peñas PF, Fernández-Herrera J, Sánchez-Pérez J, Fraga J, García-Díez A. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol 2004;18:310-313
7. Brumit MC, Shea TC, Brecher ME. Transfusion medicine illustrated. G-CSF-associated rash in an allogeneic PBPC donor. Transfusion 2003;43:1343.
8. Ferran M, Gallardo F, Salar A, Iglesias M, Barranco C, Pujol RM. Granulomatous dermatitis with enlarged histiocytes: a characteristic pattern of granulocyte colony-stimulating factor. Report of two cases and review of the literature. Dermatology 2006;212:188-193
9. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002;10:153-169
10. Schmielau J, Kalthoff H, Roeder C, Schmiegel W. The role of cytokines in pancreatic cancer. International journal of Pancreatology 1996;vol9 (3): 157-163.
11. Schmielau J, Kalthoff H, Roeder C, Schmiegel W. Cytokines in pancreatic cancer. Cell Mol Mech Pancreat Dis 1994;11:157-159.
12. Basso D, Plebani M. Cytokines and exocrine pancreatic cancer: is there a link? J Pancreas 2000;1(2):19-23.
13. Mroczko B, Szmitkowski M, Wereszczynska-Siemiatkowska U, Jurkowska G. Hematopoietic cytokines in the sera of patients with pancreatic cancer. Clin Chem Lab Med 2005;43:146-150
14. Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Mysliwiec P. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med 2007;45:30-34
15. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205
16. Lutz MP, Van Custem E, Wagener T. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 409984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 2005;23:9250-9256
17. Maxwell C, Stein A. Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: from paper to clinical practice. Community Oncol 2006;3:530-536
18. Sullivan AK, Nelson MR. Allergic skin reaction to G-CSF in a patient with AIDS [case report]. Int J STD AIDS 1997;8:135-136
19. Kawakam T, Ohashi S, Kawa Y, Takahama H, Ito M. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of Sweet syndrome and patients with active Behçet disease (implication in neutrophil apoptosis dysfunction). Arch Dermatol 2004;140:570-574
20. Fariña MC, Requena L, Dómine M, Soriano ML, Estevez L, Barat A. Histopathology of cutaneous reaction to granulocyte colony-stimulating factor: another pseudomalignancy. J Cutan Pathol 2006;25:559-562